{
  "doc_id": "shc_tpn_guidelines__081577",
  "original_filename": "SHC TPN Guidelines.pdf",
  "md_path": "data/parsed/SHC TPN Guidelines/SHC TPN Guidelines.md",
  "rmd_path": "data/parsed/SHC TPN Guidelines/SHC TPN Guidelines.rmd",
  "blocks": [
    {
      "type": "heading",
      "level": 1,
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 0
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 2,
      "preview": "I. Introduction"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 3,
      "preview": "A. Purpose"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 4,
      "preview": "B. Definition of Terms"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 5,
      "preview": "C. Indications"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 6,
      "preview": "D. Considerations"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 7,
      "preview": "E. Responsibilities"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 8,
      "preview": "II. Parenteral Nutrition Access"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 9,
      "preview": "III. Nutritional Requirements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 10,
      "preview": "A. Caloric requirements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 11,
      "preview": "B. Carbohydrates requirements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 12,
      "preview": "C. Protein requirements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 13,
      "preview": "D. Fat requirements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 14,
      "preview": "E. Vitamins"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 15,
      "preview": "F. Trace elements"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 16,
      "preview": "G. Electrolytes"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 17,
      "preview": "IV. Total Parenteral Nutrition (TPN)"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 18,
      "preview": "A. Purpose"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 19,
      "preview": "B. Initiation"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 20,
      "preview": "C. Administration"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 21,
      "preview": "D. Monitoring"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 22,
      "preview": "E. Complications"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 23,
      "preview": "V. Peripheral Parenteral Nutrition (PPN)"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 24,
      "preview": "A. Purpose"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 25,
      "preview": "B. Initiation"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 26,
      "preview": "C. Limitations"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 27,
      "preview": "D. Monitoring"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 28,
      "preview": "VI. Intravenous Fat Emulsions"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 29,
      "preview": "A. Purpose"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 30,
      "preview": "B. Administration"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 31,
      "preview": "C. Monitoring"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 32,
      "preview": "D. Complications"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 34,
      "preview": "--- page 1 ---"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 36,
      "preview": "VII. Transitional Feedings"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 37,
      "preview": "A. Cyclic TPN"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 38,
      "preview": "B. Enteral Nutrition"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 39,
      "preview": "C. Transitioning to Home TPN"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 40,
      "preview": "VIII. Appendix"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 41,
      "preview": "A. References"
    },
    {
      "type": "text",
      "section": "2024 Adult Parenteral Nutrition Guidelines Stanford Health Care",
      "line": 42,
      "preview": "B. Contributors"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "I. INTRODUCTION",
      "line": 44
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 46,
      "preview": "A. Purpose: To provide guidance in the assessment, surveillance, and provision of parenteral nutriti"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 47,
      "preview": "B. Definition of Terms: Parenteral Nutrition (PN) refers to both Central Parenteral Nutrition (CPN) "
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 49,
      "preview": "1. PN is the intravenous mode of nutrition support therapy that bypasses the gastrointestinal tract "
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 50,
      "preview": "C. Indications: The evaluation of indications and contraindications should be conducted prior to PN "
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 51,
      "preview": "2. Clinical settings where PN is likely indicated:"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 52,
      "preview": "a) Anastomotic leak/bowel perforation/GI discontinuity"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 53,
      "preview": "b) Bowel obstruction"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 54,
      "preview": "c) Distal high output enterocutaneous fistula"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 55,
      "preview": "d) Failed trial of enteral nutrition"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 56,
      "preview": "e) High output chylous leak"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 57,
      "preview": "f) High risk for bowel ischemia"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 58,
      "preview": "g) Ileus"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 59,
      "preview": "h) Inability to obtain enteral access"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 60,
      "preview": "i) Intolerance to PO/enteral nutrition"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 62,
      "preview": "--- page 2 ---"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 64,
      "preview": "j) Intractable vomiting or diarrhea"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 65,
      "preview": "k) Massive small bowel resection"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 66,
      "preview": "l) Peritonitis"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 67,
      "preview": "m) Primary team preference"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 68,
      "preview": "n) Requiring supplemental PN to meet full nutritional needs"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 69,
      "preview": "o) Severe malabsorption"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 70,
      "preview": "p) Severe mucositis"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 71,
      "preview": "q) Slow post-operative PO/EN advancement"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 72,
      "preview": "2. Clinical setting where PN is contraindicated:"
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 73,
      "preview": "a) There is a functional and accessible gastrointestinal tract."
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 74,
      "preview": "b) The use of PN is anticipated to be less than five days."
    },
    {
      "type": "text",
      "section": "I. INTRODUCTION",
      "line": 75,
      "preview": "c) When aggressive nutrition support is not warranted by the patient's wishes or prognosis."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Considerations:",
      "line": 77
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 79,
      "preview": "1. Do not use PN solely to treat poor oral intake and/or cachexia associated with advanced malignanc"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 80,
      "preview": "2. Evaluate clinical factors and performance status when selecting candidates for PN at the end of l"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 81,
      "preview": "3. Limit the use of PN in palliative care to appropriate candidates with an expected survival of at "
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 82,
      "preview": "4. Define criteria for discontinuing PN depending on the patient's goals of care; consider stopping "
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 83,
      "preview": "5. Time Frame for Initiating PN:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 84,
      "preview": "a) PPN is indicated in 2 situations: as a bridge therapy to TPN when central access cannot be obtain"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 85,
      "preview": "b) Delay the initiation of PN in a patient with severe metabolic instability until the patient's con"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 86,
      "preview": "(1) Hyperglycemia: Glucose greater than $180 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 87,
      "preview": "(2) Azotemia: Blood urea nitrogen greater than $100 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 88,
      "preview": "(3) Hypertriglyceridemia: Serum triglycerides greater than $200 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 90,
      "preview": "--- page 3 ---"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 92,
      "preview": "(4) Hyponatremia: Serum sodium less than $130 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 93,
      "preview": "(5) Hypernatremia: Serum sodium greater than $150 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 94,
      "preview": "(6) Hypokalemia: Serum potassium less than $3 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 95,
      "preview": "(7) Hypomagnesemia: Serum magnesium less than $1.3 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 96,
      "preview": "(8) Hypocalcemia: Ionized calcium less than $4.5 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 97,
      "preview": "(9) Hypophosphatemia: Serum phosphorus less than $2 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 98,
      "preview": "c) For patients who are unable to achieve the desired intake orally or through EN, PN should be init"
    },
    {
      "type": "table",
      "section": "D. Considerations:",
      "line": 100,
      "preview": "| Nutritional Status | When to initiate PN |"
    },
    {
      "type": "table",
      "section": "D. Considerations:",
      "line": 101,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "D. Considerations:",
      "line": 102,
      "preview": "| well-nourished, stable adult patients | after 7 days |"
    },
    {
      "type": "table",
      "section": "D. Considerations:",
      "line": 103,
      "preview": "| are nutritionally-at-risk | within 3 to 5 days |"
    },
    {
      "type": "table",
      "section": "D. Considerations:",
      "line": 104,
      "preview": "| baseline moderate or severe malnutrition | soon as feasible |"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 106,
      "preview": "6. High-Risk Cardiac Surgery Populations per CVICU High-Risk EN Guidelines:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 107,
      "preview": "a) POD 0-1: Initiate TPN if severely malnourished and EN is not feasible."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 108,
      "preview": "b) POD 3: Exclusive or supplemental TPN if no malnutrition and unable (or anticipated barriers) to m"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 109,
      "preview": "E. Responsibilities: It is incumbent upon all medical providers who provide direct patient care to u"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 110,
      "preview": "7. Licensed Independent Practitioner: assumes ultimate responsibility for management decisions relat"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 111,
      "preview": "a) Orders the PN therapy, the solution, additives, infusion time, and duration."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 112,
      "preview": "b) Orders the placement of the catheter as well as nursing care."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 113,
      "preview": "c) Monitors, assesses, and responds to adverse effects."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 114,
      "preview": "d) Evaluates appropriateness of initiating and continuing PN in partnership with the dietitian."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 115,
      "preview": "8. Pharmacist:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 116,
      "preview": "a) Assesses and provides recommendations to adjust PN additives (components) as needed."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 117,
      "preview": "b) Coordinates compounding, labeling, and dispensing of the PN solution."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 118,
      "preview": "c) Monitors parameters influenced by PN additives."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 119,
      "preview": "9. Registered Nurse:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 120,
      "preview": "a) Administers the solution."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 122,
      "preview": "--- page 4 ---"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 124,
      "preview": "b) Provides line and access care."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 125,
      "preview": "c) Monitors for adverse effects."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 126,
      "preview": "4. Registered Dietitian:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 127,
      "preview": "a) Determines nutritional requirements."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 128,
      "preview": "b) Monitors the appropriateness of PN therapy in partnership with the provider."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 129,
      "preview": "c) Assesses and provides recommendations to adjust PN additives (components) as needed."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 130,
      "preview": "d) Monitors for adverse effects."
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 131,
      "preview": "5. Case Manager:"
    },
    {
      "type": "text",
      "section": "D. Considerations:",
      "line": 132,
      "preview": "a) Coordinates interdisciplinary discharge planning process for home PN therapy."
    },
    {
      "type": "heading",
      "level": 1,
      "section": "II. PARENTERAL NUTRITION ACCESS",
      "line": 134
    },
    {
      "type": "text",
      "section": "II. PARENTERAL NUTRITION ACCESS",
      "line": 136,
      "preview": "A. Please refer to the following procedure in the Patient Care Manual for more information: Intraven"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 138
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 140,
      "preview": "A. Caloric Requirements: The Registered Dietitian determines the appropriate energy goal based on va"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 142,
      "preview": "1. In general, ASPEN guidelines recommend a range of 20 to $35 \\mathrm{kcals} / \\mathrm{kg}$ when ca"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 143,
      "preview": "2. Indirect Calorimetry (IC) is considered the gold standard for determining metabolic rate. When pr"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 144,
      "preview": "B. Carbohydrate Requirements: The minimum recommended amount is 100 grams of carbohydrates for adult"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 145,
      "preview": "3. Dextrose provides 3.4 kilocalories/g. To minimize adverse metabolic consequences (e.g., hyperglyc"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 147,
      "preview": "--- page 5 ---"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 149,
      "preview": "infusion of carbohydrates should not exceed $5 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$. Patients o"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 150,
      "preview": "C. Protein Requirements: Requirements range from $0.8-2.5 \\mathrm{~g} / \\mathrm{kg} /$ day depending"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 152,
      "preview": "| Protein Dose | Condition |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 153,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 154,
      "preview": "| $0.8-1.0 \\mathrm{~g} / \\mathrm{kg}$ | Well-nourished and non-stressed and CKD stage 3-4 not on dia"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 155,
      "preview": "| $1.0-1.2 \\mathrm{~g} / \\mathrm{kg}$ | Well-nourished and non-stressed, moderately active |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 156,
      "preview": "| $1.2-1.5 \\mathrm{~g} / \\mathrm{kg}$ | Malnourished or stressed (ex., Post-op, wounds, intermittent"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 157,
      "preview": "| $1.5-2.0 \\mathrm{~g} / \\mathrm{kg}$ | Malnourished and/or severely stressed, or overweight/obese ("
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 158,
      "preview": "| $2.0-2.5 \\mathrm{~g} / \\mathrm{kg}$ | Malnourished, obese, severe whole body trauma, CRRT |"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 160,
      "preview": "1. Protein provides 4 kilocalories/g."
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 161,
      "preview": "D. Fat Requirements: Essential fatty acid (EFA) deficiency occurs when less than 4\\% kilocalories ar"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 162,
      "preview": "2. SMOFLipids (soybean, MCT, olive oil, fish oil):"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 163,
      "preview": "a) The usual daily dosage in adults is 1 to 2 grams $/ \\mathrm{kg}$ per day and should not exceed 2."
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 164,
      "preview": "b) SMOFlipid is a lipid injectable emulsion with a lipid content of $0.2 \\mathrm{~g} / \\mathrm{mL}$ "
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 165,
      "preview": "c) Hypersensitivity Reactions"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 166,
      "preview": "(1) SMOFlipid contains soybean oil, fish oil, peanut, and egg phospholipids, which may cause hyperse"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 167,
      "preview": "E. Vitamins: Multiple vitamins for infusion (MVI) given daily will supply the recommended daily intr"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 169,
      "preview": "--- page 6 ---"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 171,
      "preview": "1. Standard daily parenteral multivitamin Infuvite ${ }^{\\circledR}$ for adults are as follows:"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 173,
      "preview": "| Thiamine | 6 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 174,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 175,
      "preview": "| Riboflavin | 3.6 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 176,
      "preview": "| Niacin | 40 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 177,
      "preview": "| Folic acid | 600 mcg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 178,
      "preview": "| Pantothenic acid | 15 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 179,
      "preview": "| Vitamin B-6 | 6 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 180,
      "preview": "| Vitamin B-12 | 5 mcg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 181,
      "preview": "| Biotin | 60 mcg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 182,
      "preview": "| Choline | Not Defined |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 183,
      "preview": "| Vitamin C | 200 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 184,
      "preview": "| Vitamin A | 1 mg (3300 IU) |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 185,
      "preview": "| Vitamin D | 5 mcg (200 IU) |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 186,
      "preview": "| Vitamin E | 10 mg (10 IU) |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 187,
      "preview": "| Vitamin K | 150 mcg |"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 189,
      "preview": "F. Trace Elements: The addition of trace elements should be individualized according to patient need"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 191,
      "preview": "Exceptions should be made for patients on CRRT, who have higher copper needs. Even in the setting of"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 193,
      "preview": "1. Trace elements provision in standard 1 mL Tralement ${ }^{\\circledR}$ solution are as follows:"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 195,
      "preview": "| Copper | 0.3 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 196,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 197,
      "preview": "| Manganese | 55 mcg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 198,
      "preview": "| Selenium | 60 mcg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 199,
      "preview": "| Zinc | 3 mg |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 200,
      "preview": "| Fluoride | Not routinely added |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 201,
      "preview": "| Iodine | Not routinely added |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 202,
      "preview": "| Iron | Not routinely added due to |"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 204,
      "preview": "--- page 7 ---"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 206,
      "preview": "|  | compatibility limitations |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 207,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 208,
      "preview": "| Molybdenum | Not routinely added |"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 210,
      "preview": "G. Electrolytes: Requirements are extremely variable and must be individualized."
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 212,
      "preview": "1. General guidelines for reasonable daily amounts in parenteral nutrition are as follows:"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 214,
      "preview": "| Sodium | $1-2 \\mathrm{mEq} / \\mathrm{kg}$ (up to $154 \\mathrm{mEq} / \\mathrm{L}$ ) |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 215,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 216,
      "preview": "| Potassium | $1-2 \\mathrm{mEq} / \\mathrm{kg}$ (10 to $30 \\mathrm{mEq} / \\mathrm{d}$ is generally |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 217,
      "preview": "|  | sufficient to prevent hypokalemia) |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 218,
      "preview": "| Calcium | $10-15 \\mathrm{mEq}$ |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 219,
      "preview": "| Magnesium | $8-20 \\mathrm{mEq}$ |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 220,
      "preview": "| Phosphorus | $20-40 \\mathrm{mmol}$ |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 221,
      "preview": "| Chloride | as needed to maintain acid-base balance |"
    },
    {
      "type": "table",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 222,
      "preview": "| Acetate | as needed to maintain acid-base balance |"
    },
    {
      "type": "text",
      "section": "III. NUTRITIONAL REQUIREMENTS",
      "line": 224,
      "preview": "2. Consider using oral or enterally administered multivitamins, electrolytes, or mineral products wh"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 226
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 228,
      "preview": "A. This is a hypertonic solution that requires infusion through a central line. It allows sufficient"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 229,
      "preview": "B. Initiation"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 231,
      "preview": "1. Confirm placement or access of a central venous catheter."
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 232,
      "preview": "2. Enter initial orders in the IP GEN TPN/PPN Adult Protocol Order Set in the Electronic Medical Rec"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 233,
      "preview": "3. Renew TPN daily by entering an order in the EMR."
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 234,
      "preview": "4. Providers must enter the order in Epic or give a verbal order with readback to the pharmacist by "
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 235,
      "preview": "C. Administration"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 236,
      "preview": "5. When initiating TPN, check blood glucose levels every 6 hours for the first 24 hours."
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 238,
      "preview": "--- page 8 ---"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 240,
      "preview": "2. If TPN must be suddenly stopped, check blood glucose within 30 to 60 minutes and monitor for hypo"
    },
    {
      "type": "text",
      "section": "IV. TOTAL PARENTERAL NUTRITION (TPN)",
      "line": 241,
      "preview": "3. When stopping TPN, decrease the rate by $50 \\%$ for 1 to 2 hours before discontinuation to minimi"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "D. Monitoring",
      "line": 243
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 245,
      "preview": "1. The following labs are recommended prior to starting parenteral nutrition:"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 246,
      "preview": "a) Comprehensive Metabolic Panel"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 247,
      "preview": "b) Phosphorus, Magnesium"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 248,
      "preview": "c) Triglycerides"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 249,
      "preview": "d) Direct bilirubin"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 250,
      "preview": "2. The following are recommended while the patient is on parenteral nutrition:"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 251,
      "preview": "a) Basic Metabolic Panel, Phosphorus, and Magnesium daily, then weekly once stable"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 252,
      "preview": "b) Triglycerides, liver function tests, and direct bilirubin once weekly"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 253,
      "preview": "c) CBC once weekly"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 254,
      "preview": "d) Other labs as needed"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 255,
      "preview": "3. Albumin and prealbumin are not sensitive or specific enough to have any value in assessing nutrit"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 256,
      "preview": "E. Complications: Common complications can be divided into three groups: mechanical, metabolic, and "
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 257,
      "preview": "4. Mechanical: Mechanical complications occur in up to 5\\% of PN patients. Please see CVC procedures"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 258,
      "preview": "a) Central Venous Catheter - Insertion, Maintenance, Patency, and Removal found at Central Vascular "
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 259,
      "preview": "Central Venous Catheter - Peripherally Inserted Central Catheter (PICC) Insertion and Exchange found"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 260,
      "preview": "5. Metabolic: Below is a table of possible metabolic complications and appropriate interventions."
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 262,
      "preview": "| Complications | Possible Etiology | Interventions |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 263,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 264,
      "preview": "| A. Abnormalities related to metabolic disorders of the patient |  |  |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 265,
      "preview": "| Hyperglycemia (with <br> resultant dextrose <br> glycosuria, osmotic | - Excessive intake (either "
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 267,
      "preview": "--- page 9 ---"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 269,
      "preview": "| diuresis rate, and possible dehydration) | - Change in metabolic rate (sepsis, surgical stress)"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 270,
      "preview": "- Medications: steroids, octreotide | - Carbohydrate administration should not exceed a rate of $4-5"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 271,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 272,
      "preview": "| Hypoglycemia | - Sudden cessation of infusion <br> - Excessive administration of insulin | - If PN"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 273,
      "preview": "| Electrolyte disorders | - Excessive or inadequate intake | - PN electrolyte changes based on clini"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 274,
      "preview": "| Mineral disorders | - Excessive or inadequate intake | - PN mineral changes based on clinical asse"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 276,
      "preview": "--- page 10 ---"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 278,
      "preview": "| Trace element disorders | - Excessive or inadequate intake | - PN trace element changes based on c"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 279,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 280,
      "preview": "| Essential fatty acid deficiency | - Inadequate intake | - Provide 20\\% IV lipids 250 mL twice week"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 281,
      "preview": "| Hypertriglyceridemia | - Dextrose overfeeding <br> - Poor glycemic control <br> - Rapid administra"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 282,
      "preview": "| Acid-base Imbalance | - Use of hydrochloride salts of cationic electrolytes or inadequate administ"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 283,
      "preview": "| Azotemia | - Dehydration, excess protein, and/or inadequate nonprotein calories <br> - Patients wi"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 285,
      "preview": "--- page 11 ---"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 287,
      "preview": "| Refeeding Syndrome | - Aggressive nutrition support, especially in severely malnourished patients,"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 288,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 289,
      "preview": "| Respiratory Failure | - Overfeeding causing elevated $\\mathrm{CO}_{2}$ production and increased re"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 290,
      "preview": "| B. Miscellaneous |  |  |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 291,
      "preview": "| Congestive Heart Failure | - Excessive rapid infusion of PN solution <br> - Pulmonary edema | - Co"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 292,
      "preview": "| Anemia | - Failure to replace blood loss, iron deficiency | - Iron repletion per primary team. |"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 293,
      "preview": "| Demineralization of bone | - Inactivity, inadequate intake of calcium and phosphate, and/or inadeq"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 294,
      "preview": "| Hepatic disorders <br> - Steatosis | - Concerning for long-term PN support $>2$ weeks | - Remove m"
    },
    {
      "type": "text",
      "section": "D. Monitoring",
      "line": 296,
      "preview": "--- page 12 ---"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 298,
      "preview": "| - Cholestasis <br> - Biochemical and histopathologic tract abnormalities | - Excessive <br> lipid/"
    },
    {
      "type": "table",
      "section": "D. Monitoring",
      "line": 299,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 301
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 303,
      "preview": "A. This solution contains amounts of dextrose and amino acids in concentrations that may be administ"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 304,
      "preview": "B. Initiation:"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 306,
      "preview": "1. Order entry follows the same guidelines and process as TPN (see section IV)"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 307,
      "preview": "2. A new peripheral catheter should be placed prior to starting PPN."
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 308,
      "preview": "C. Limitations:"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 309,
      "preview": "3. The osmolarity of the final PPN mixture should not exceed $1100 \\mathrm{mOsm} / \\mathrm{L}$."
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 310,
      "preview": "4. Due to limitations in osmolarity and volume, PPN solutions may provide inadequate nutrition for s"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 311,
      "preview": "5. The recommended use for PPN is 5-14 days. Consider TPN if PPN provides insufficient nutrition and"
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 312,
      "preview": "6. Patients cannot be discharged to home on PPN."
    },
    {
      "type": "text",
      "section": "V. PERIPHERAL PARENTERAL NUTRITION (PPN)",
      "line": 313,
      "preview": "D. Monitoring: Similar to TPN, routine monitoring of metabolic and nutritional parameters is recomme"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 315
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 317,
      "preview": "A. Purpose: Fat emulsion may be used as a concentrated caloric source and as a source of essential f"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 319,
      "preview": "--- page 13 ---"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 321,
      "preview": "the US have been soybean oil based. In 2016, the FDA approved a new combination product, SMOFlipid, "
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 322,
      "preview": "B. Administration:"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 324,
      "preview": "1. Specify volume, concentration (20\\%), and administration rate for fat emulsion in order entry."
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 325,
      "preview": "2. Fat Emulsion Hang-Time: Per CDC guidelines, fat emulsions should be hung for a 12-hour time perio"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 326,
      "preview": "3. For more information, please see Intravenous Infusion - Parenteral Nutrition TPN, PPN, Lipid Emul"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 327,
      "preview": "C. Monitoring: Liver function tests, prothrombin time, and platelets should be ordered at least once"
    },
    {
      "type": "text",
      "section": "VI. INTRAVENOUS FAT EMULSION",
      "line": 328,
      "preview": "D. Complications: Hypertriglyceridemia can occur if fat emulsion is administered at a rate > $0.11 \\"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 330
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 332,
      "preview": "A. Cyclic TPN: Parenteral Nutrition should be initiated as a 24-hour continuous infusion prior to cy"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 333,
      "preview": "B. Enteral Nutrition: Before transitioning off TPN, adequate enteral intake must be attained. After "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 335,
      "preview": "1. TPN is decreased as enteral intake is increased in order for total intake to meet nutritional nee"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 337,
      "preview": "--- page 14 ---"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 339,
      "preview": "C. Transitioning to Home TPN: Prior to starting home TPN, it must be determined if the burden of hom"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 341,
      "preview": "1. Cultural/religious values."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 342,
      "preview": "2. Ability for patient or caregiver to manage home TPN (comprehension, manual dexterity, and the abi"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 343,
      "preview": "3. Home safety (clean environment with storage capability, non-hostile environment)."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 344,
      "preview": "4. Access to care (an outpatient provider willing to oversee the TPN, infusion, and home care nursin"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 345,
      "preview": "5. Health insurance and costs."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 346,
      "preview": "a) Once a patient is determined as an appropriate candidate for TPN, he/she should be clinically sta"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 347,
      "preview": "b) The primary team must identify an outpatient provider who will continue to sign the TPN orders an"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 348,
      "preview": "VIII. APPENDIX"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 349,
      "preview": "A. References:"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 350,
      "preview": "6. Ayers P, Adams S, Boullata J, et al. A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendat"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 351,
      "preview": "7. Ayers P, Bobo E, Hurt R, Mays A, Worthington P. ASPEN Parenteral Nutrition Handbook: Third Editio"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 352,
      "preview": "8. Barr LH, Dunn GD, Brennan MF. Essential fatty acid deficiency during total parenteral nutrition. "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 353,
      "preview": "9. Berger MM, Shenkin A, Schweinlin A, et al. ESPEN micronutrient guideline. Clin Nutr. 2022 Jun;41("
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 354,
      "preview": "10. Crill CM, Hak EB, Robinson LA. Evaluation for microbial contamination associated with different "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 356,
      "preview": "--- page 15 ---"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 358,
      "preview": "6. Crocker KS, Noga R, Filibeck DJ, et al. Microbial growth comparisons of five commercial parentera"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 359,
      "preview": "7. DeDonato BM, Bickford LI and Gates RJ. Microbial growth in neonatal intravenous fat emulsion admi"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 360,
      "preview": "8. Ellery G, Stanner H, Lockwood S, et al. Utilization of Topical Safflower Oil in the Treatment of "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 361,
      "preview": "9. Gramlich L, Ireton-Jones C, Miles JM, Morrison M, Pontes-Arruda A. Essential Fatty Acid Requireme"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 362,
      "preview": "10. McClave SA, Taylor BE, Martindale RG, et al. Guidelines for the provision and assessment of nutr"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 363,
      "preview": "11. Merritt RM (ed). The A.S.P.E.N. Nutrition Support Practice Manual. 2nd ed. Silver Spring, MD: Am"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 364,
      "preview": "12. Mirtallo J, Canada T, Johnson D, et al.; A.S.P.E.N. Board of Directors and Task Force for the Re"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 365,
      "preview": "13. Mogensen KM. Essential Fatty Acid Deficiency. Nutrition Issues in Gastroenterology. 2017."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 366,
      "preview": "14. Mueller C (ed). The A.S.P.E.N. Adult Nutrition Support Core Curriculum. 2nd ed. Silver Spring, M"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 367,
      "preview": "15. Mueller C. The ASPEN Adult Nutrition Support Core Curriculum. 3rd ed. Silver Spring, MD: America"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 368,
      "preview": "16. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 369,
      "preview": "17. Vanek VW, Seidner DL, Allen P, et al. A.S.P.E.N. position paper: Clinical role for alternative i"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 370,
      "preview": "18. Worthington P, Bechtold M, Bingham A, et al. When is Parenteral Nutrition Appropriate? JPEN J Pa"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 371,
      "preview": "B. Contributors:"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 372,
      "preview": "19. ORIGINALLY PUBLISHED IN 1996 BY THE TOTAL PARENTERAL NUTRITION COMMITTEE CONTRIBUTORS TO THE 201"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 374,
      "preview": "--- page 16 ---"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 376,
      "preview": "a) Ron Pearl, M.D.; Paul Maggio, M.D.; Trevor Winter, M.D.; Marina Basina, M.D.; Lynn Dennie, R.D., "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 377,
      "preview": "b) Reviewed and approved by the Nutrition Committee: March 22, 2013"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 378,
      "preview": "c) Reviewed and approved by the Pharmacy \\& Therapeutics Committee: (Date lost)"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 379,
      "preview": "2. CONTRIBUTORS TO THE 2016 REVISION"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 380,
      "preview": "a) Jami Baltz, RD, CNSC; Yvonne Best, MS, RD; Qingshan (Sandy) Sun, MS, RD Neha Shah, MPH, RD, CNSC "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 381,
      "preview": "(1) Reviewed and approved by the Nutrition Committee: 7/7/2016"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 382,
      "preview": "(2) Reviewed and approved by the Pharmacy \\& Therapeutics Committee: (Date lost)"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 383,
      "preview": "3. CONTRIBUTORS TO THE 2018 REVISION"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 384,
      "preview": "a) Janine Berta, MS, RD, CNSC, Martino Maranghi, MS, RD, CNSC, Leanna Tu, MS, RD, Andrea Wolf, RD, C"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 385,
      "preview": "b) Reviewed and approved by the Nutrition Committee: 2/15/2018"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 386,
      "preview": "c) Reviewed and approved by the Pharmacy \\& Therapeutics Committee: 2/16/2018."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 387,
      "preview": "4. CONTRIBUTORS TO THE 2021 REVISION"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 388,
      "preview": "a) Janine Berta, MS, RD-AP, CNSC, May Carr, MS, RD, CNSC, CSO, Natalie Chan, RD, CNSC, CCTD, Katie M"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 389,
      "preview": "b) Reviewed and approved by the Nutrition Committee: 10/2021"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 390,
      "preview": "c) Reviewed and approved by the Pharmacy \\& Therapeutics Committee: $11 / 2021$"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 391,
      "preview": "5. CONTRIBUTORS TO THE 2024 REVISION"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 392,
      "preview": "a) Janine Berta, MS, RD-AP, CNSC, Chunyun Xiao, MCN, RD-AP, CSO, CNSC, CMI, FAND, Ann Hill, MS, RD, "
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 393,
      "preview": "b) Reviewed and approved by the Nutrition Committee: 9/2024"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 394,
      "preview": "c) Reviewed and approved by the Pharmacy \\& Therapeutics Committee: 2/2025"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 395,
      "preview": "d) Addendum to Section III, part F"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 396,
      "preview": "(1) Janine Berta, MS, RD-AP, CNSC, Ranna Modir, MS, RD, CDECS, CNSC, CCTP"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 397,
      "preview": "(2) Reviewed and Approved by Nutrition Committee: 2/2025"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 399,
      "preview": "--- page 17 ---"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 401,
      "preview": "(3) Reviewed and Approved by Pharmacy \\& Therapeutics Committee: $3 / 2025$"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 402,
      "preview": "e) Addendum to Section V, part A"
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 403,
      "preview": "(1) Janine Berta, MS, RD-AP, CNSC, April Fong, Pharm D. Cherywn Nguyen, Pharm D."
    },
    {
      "type": "text",
      "section": "VII. TRANSITIONAL FEEDINGS",
      "line": 404,
      "preview": "(2) Reviewed and Approved by Nutrition Committee: 5/2025"
    }
  ],
  "images": [],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696503",
    "ts": "2025-08-08T23:41:43.065924+00:00"
  }
}